A case of retinal tear associated with use of sorafenib
Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhib...
Main Authors: | Kelly M. Gaertner, Stephen H. Caldwell, Osama eRahma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00196/full |
Similar Items
-
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01) -
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
by: Sojung Han, et al.
Published: (2020-07-01) -
Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
by: Jeong-Ju Yoo, et al.
Published: (2019-03-01) -
Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
by: Zhang E, et al.
Published: (2020-12-01) -
Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
by: Chunjiang Wu, et al.
Published: (2015-10-01)